Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subretinal Macugen for neovascular age-related macular degeneration (SUMANA)
2007-006290-90Phase 3Active
- Sponsor
- Society for Clinical Research Sites
- Start
- Jan 2009
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of pegaptanib sodium in age-related macular degeneration (AMD), sponsored by Society for Clinical Research Sites. Primary endpoint: Proportion of patients with fewer than 15-letter visual acuity loss at 54 weeks. Started Jan 2009; status: active.
02
Drugs
pegaptanib sodium
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2007-006290-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006290-90.